Patrickj Mcenany News Today

CPRX | Complete Catalyst Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Catalyst Ranked #4 on the ListCORAL GABLES, Fla., Dec. 05, 2023 -- Catalyst Pharmaceuticals, Inc. today announced its inclusion in Forbes esteemed list of Americas Most Successful Small-Cap...

Ms. Alicia Grande, Catalysts Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...

     Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $ Diluted, Impacted by an $81.5 Million One Time Non-Recurring...

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results ...

CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,

The drug’s mode of action is different than other types of corticosteroids because it’s based on the differential effects on glucocorticoid and mineralocorticoid receptors.

New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio...

The drug’s mode of action is different than other types of corticosteroids because it’s based in the differential effects on glucocorticoid and mineralocorticoid receptors.

26.10.2023 - AGAMREE Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential ... Seite 1